Latest Revenue Growth News

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

ReadCloud Limited’s 1H26 results reveal robust growth in school-focused businesses, with cash receipts up 22% and operating cash flow rising 10%, positioning the company to outperform its FY26 earnings guidance.

Aspermont Limited (ASX:ASP) reported a 147% jump in net profit and 11% revenue growth for H1 FY26, driven by steady subscription growth and a ramp-up in non-subscription revenues. The company’s self-funded data and intelligence platform is on track, with Rio Tinto’s enterprise contract validating its strategic pivot.

Australian Clinical Labs appoints Greg Horan as Group CEO effective August 2026, marking a leadership transition after a decade under Melinda McGrath. Horan’s healthcare and operational expertise positions ACL for its next growth phase.

Zoono Group has secured its first major commercial orders worth NZ$600,000 from Sharpak under an exclusive UK soft fruits packaging contract, marking a key step in scaling its antimicrobial coating technology in international markets.

Promisia Healthcare reported a robust 29% increase in operating revenue for FY26, alongside a new dividend policy tied to operating free cash flow, setting the stage for continued growth in FY27.

Mainfreight reported a 2.8% revenue increase to NZ$5.38 billion for FY26, but profit before tax declined 8.5% to NZ$350.9 million, weighed down by higher overheads and regional challenges. The company declared a steady final dividend and outlined ongoing network expansion plans.

Qoria Limited is moving towards a transformative merger with US-based Aura Consolidated Group, Inc., combining complementary digital safety platforms and targeting growth through a $100 million capital raise and ASX listing.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Dicker Data has outperformed its FY25 guidance, delivering a 14.9% jump in gross revenue to $3.876 billion, fuelled by AI deals and infrastructure refreshes. The company’s FY26 outlook anticipates continued momentum in AI and data centre projects despite pricing pressures.

Knosys has locked in a two-year, $3.8 million contract extension with ANZ, with full payment received upfront. This deal underpins Knosys’s role in ANZ’s AI integration efforts and strengthens the company’s cash position.

Ainsworth Game Technology posted a 10% revenue increase in FY25 to $291 million, driven by strong Asia Pacific growth, while North American challenges weigh on H1 2026 outlook.